Engineered peptides block osteopontin interactions with macrophages and microglia, limiting glioma invasiveness and supporting anti-PD1 therapy.
Synthetic peptides target respiratory viruses in epithelial cells, addressing limited antiviral efficacy and adverse effects without disrupting cellular structures.
This case addresses complex viral-like delivery systems with polypeptides that encapsulate oligonucleotides for cellular uptake.
Synthetic antigens targeting the P. vivax DBPII ligand domain inhibit erythrocyte invasion while addressing drug-resistant strains and relapse risk.
Modular polypeptide domains and tuner proteins set above- or below-threshold responses, controlling protein activity, stability, and localization.
Selective protection, nanofiltration, and organic coupling agents help produce high-purity tirzepatide with fewer purification steps and less waste.
Novel protected intermediates, nanofiltration, and selective lysine acylation support high-purity tirzepatide with less waste.
Collagenase releases protease-resistant ECM peptides that stimulate new hair follicle formation and support wound healing during radiation treatment.
This case uses docking, molecular dynamics, and multi-parameter optimization to design stable peptide receptors for glucose biosensors.
A dual-ring peptide architecture pairs cell-penetrating and NEMO-binding sequences to inhibit NEMO–IKK signaling.
Cysteine peptides form disulfide bonds with keratin to shape hair, reduce breakage, and retain effects after washing.
Cationic lipid–peptide complexes improve nucleic acid delivery into difficult-to-transfect cells with low toxicity.
Hydrophobic and polar peptoid polymers inhibit subzero ice formation, supporting longer organ preservation with less tissue toxicity.
Branched PEG with intracellularly cleavable linkages preserves blood stability and half-life while reducing vacuole formation.
Aqueous γ-cyclodextrin host-guest processing enables site-specific bioconjugation with less purification, supporting scalable SAP synthesis.
De novo polypeptides with optional linkers target EpCAM and PDL1 at nanomolar affinity while improving tumor penetration.
This case combines GLP-1, GCG, and GIP activity in one polypeptide for glucose and weight control with weekly action.